Author(s): Xuemei Jin, Chunyan Liu, Huanhuan Du, Xiaojun Chen and Bin Yu

Abstract: The traditional Mongolian remedy Ruxian-I has exhibited significant therapeutic efficacy on breast hyperplasia. To elucidate the potential pathogenesis of breast hyperplasia and the therapeutic mechanism of Ruxuan-I, we employed transcriptome technology to analyze alterations in gene expression profiles, functional categories, and molecular pathways associated with both untreated breast hyperplasia and its treatment with Ruxuan-I. Our findings suggest that the upregulation of ER-? gene expression levels regulated by HPO and pathways related to inflammation and immunity may play pivotal roles in the development of breast hyperplasia. Furthermore, our drug testing results indicate that Ruxian-I may exert its therapeutic effects through immune-related pathways. This study provides valuable insights into the potential causes of breast hyperplasia as well as the therapeutic mechanism of Ruxian-I. Further investigation into these gene alterations and active ingredients within Ruxian-I will be instrumental in advancing our understanding of both the pathogenesis and treatment strategies for breast hyperplasia.

DOI: 10.22271/flora.2025.v13.i4b.1004